Latest News

TAMPA, Fla. — Pancreatic cancer presents a challenging prognosis, marked by a five-year overall survival rate of merely 12.5%. Diagnosis frequently occurs at an advanced stage, characterized by metastasis to distant sites. The intricate molecular mechanisms governing pancreatic cancer metastasis remain a subject of ongoing research and exploration. In a recent...
SAN DIEGO, CA – Dermata Therapeutics, Inc., a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced the issuance of a new patent in Japan for its DMT410 program for the treatment of hyperhidrosis. The patent, entitled “Compositions for the treatment of skin conditions,” (Japanese...
Sitting in his favorite tiny red wooden chair, Teddy Christiansen peers out the window, smiling as he watches his older sister, Raelyn, play in the front yard. Before long, Teddy springs from the chair, itching to go outside himself. The bespectacled 33-month-old is everything he should be at his age:...
New York, NY – The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Developing Biological Markers to Improve Clinical Care in Autism” on Tuesday, February 13, 2024, at 2:00 pm ET. The presenter will be James McPartland, Ph.D., Harris Professor of Child Psychiatry and Psychology at Yale School...
Matsuyama, Japan – Multiple myeloma still appears to be an incurable hematological malignancy. One of the reasons is that myeloma cells can be heterogenous and acquire resistance after anti-myeloma treatment. Immunotherapy is an attractive strategy to target myeloma cells with drug resistance. The next-generation modality which can safely and effectively...
BOSTON, Mass. — Dewpoint Therapeutics Inc., a biotechnology company that translates the novel science of condensates into breakthrough therapeutics, today announced the filing of multiple patent applications covering novel compounds and their use in the potential treatment of amyotrophic lateral sclerosis (ALS). Composition of matter covered by these applications aims...